ReShape Lifesciences (RSLSD) Stock Price, News & Analysis

Company Overview

ReShape Lifesciences Inc. is a medical device company focused on the development and commercialization of minimally invasive, endoscopically delivered therapies for obesity and metabolic diseases. The company’s technology platform is designed to address the growing global need for nonsurgical weight-loss solutions by combining novel device engineering with established clinical protocols.

The company’s lead product, the ReShape Duo Intragastric Balloon System, consists of two connected balloons that are endoscopically placed in the stomach to reduce stomach volume and promote early satiety. The ReShape Duo system has been granted CE mark approval in Europe and is supported by clinical data demonstrating significant weight-loss outcomes when used in conjunction with dietary and behavioral counseling. ReShape Lifesciences is also pursuing regulatory clearance in the United States and exploring next-generation iterations of its balloon technology.

Originally incorporated as ReShape Medical in 2010, the company reorganized under Chapter 11 in 2019 and emerged under its current name to streamline operations and refocus its product pipeline. ReShape devices are commercially available in select European and Middle Eastern markets, and the company conducts ongoing clinical trials in North America to support U.S. regulatory submissions. ReShape Lifesciences trades on the OTC Pink under the symbol RSLSD and maintains a broad patent portfolio covering its intragastric balloon technologies.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 6,500 shs
• Average Volume: 1,362 shs
• Market Capitalization: $1.90 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Surgical, Medical, And Dental Instruments And Supplies
• Sub-Industry: Medical Equipment
• Current Symbol: OTCMKTS:RSLSD
• CIK: N/A
• Web: www.reshapelifesciences.com
• Phone: 949-429-6680
• Fax: N/A
• Employees: 50
• Year Founded: 2002

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$81.15 million
• Net Margins: -668.58%
• Pretax Margin: N/A
• Return on Equity: -163.22%
• Return on Assets: -52.10%

Debt

• Debt-to-Equity Ratio: 0.05
• Current Ratio: 1.17
• Quick Ratio: 1.07

Sales & Book Value

• Annual Sales: $610 thousand
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: 0.08
• Book Value: $341.84 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 354,000
• Free Float: N/A
• Market Cap: $1.90 million
• Optionable: Not Optionable
• Beta: 2.03